Tus%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd

## TUSQ-QD ### Overview TUSQ-QD is a combination product containing **tuberculosis (TB) medications** for treatment. The specific components are not fully detailed in the provided drug name, but typical components in TB treatment regimens include isoniazid, rifampin, pyrazinamide, and ethambutol. The "QD" designation implies once-daily dosing. ### Primary Indications Treatment of active tuberculosis. ### Adult Dosing Dosing depends on the specific formulation and the patient's weight and TB disease classification (e.g., intensive phase vs. continuation phase). A typical intensive phase regimen might include: * **Isoniazid:** 5 mg/kg/day (max 300 mg/day) * **Rifampin:** 10 mg/kg/day (max 600 mg/day) * **Pyrazinamide:** 25 mg/kg/day (max 2000 mg/day) * **Ethambutol:** 15 mg/kg/day (max 1000 mg/day) *Note: Fixed-dose combinations are common and may have different ratios. Specific dosing must follow established treatment guidelines (e.g., CDC, WHO) or local public health protocols based on patient weight and disease severity.* ### Pediatric Dosing Pediatric dosing is weight-based and follows similar principles to adult dosing, but specific formulations and ratios may vary. Always consult pediatric TB treatment guidelines. * **Isoniazid:** 10 mg/kg/day (max 300 mg/day) * **Rifampin:** 10-15 mg/kg/day (max 600 mg/day) * **Pyrazinamide:** 20-30 mg/kg/day (max 2000 mg/day) * **Ethambutol:** 15-25 mg/kg/day (max 1000 mg/day) *Note: Dosing for children younger than 12 years is often distinct. Fixed-dose combinations are available but must be carefully selected for appropriate pediatric weight bands.* ### Dose Adjustments * **Hepatic Impairment:** Use with caution. Pyrazinamide and isoniazid are hepatically metabolized. Rifampin can also cause liver injury. Dose reduction or discontinuation may be necessary. * **Renal Impairment:** Dose adjustments may be needed for pyrazinamide and ethambutol if creatinine clearance is significantly reduced (<30 mL/min). Isoniazid and rifampin generally do not require dose adjustment for renal impairment alone, but consider accumulation if hepatic function is also impaired. ### Contraindications * Hypersensitivity to any component of the drug. * Severe hepatic damage. * Concurrent use of ritonavir-boosted protease inhibitors (due to rifampin). ### Adverse Effects * **Hepatotoxicity:** Most serious; monitor liver function tests. * **Gastrointestinal:** Nausea, vomiting, anorexia. * **Neurological:** Peripheral neuropathy (isoniazid; can be mitigated with pyridoxine), dizziness, headache. * **Hematological:** Thrombocytopenia, hemolytic anemia (rifampin). * **Ocular:** Optic neuritis (ethambutol; requires baseline and periodic eye exams). * **Dermatological:** Rash, pruritus. * **Other:** Orange-red discoloration of body fluids (rifampin), hyperuricemia (pyrazinamide). ### Key Drug Interactions * **CYP450 Inducers (Rifampin):** Significantly reduces the efficacy of numerous drugs including warfarin, oral contraceptives, corticosteroids, antiretrovirals, and antifungals. * **CYP450 Inhibitors (Isoniazid):** Can increase levels of phenytoin, carbamazepine, and theophylline. * **Antacids:** May decrease absorption of rifampin. Separate administration. * **Probenecid:** May increase serum levels of ethambutol. * **Pyrazinamide:** Additive effect with other drugs known to cause hyperuricemia. ### Monitoring * **Baseline and periodic liver function tests (LFTs).** * **Baseline and periodic renal function tests.** * **Baseline and periodic visual acuity and color vision testing (for ethambutol).** * **Pyridoxine supplementation** (typically 10-25 mg daily) for patients at risk of isoniazid-induced neuropathy (e.g., diabetics, alcoholics, HIV-infected individuals, pregnant women). * **Sputum microscopy and culture** to assess treatment response. * **Monitor for signs/symptoms of adverse effects.** ### Clinical Pearls * Fixed-dose combination products simplify adherence but require careful selection to ensure appropriate dosing for individual patients. * Ensure patients are aware of the orange-red discoloration of bodily fluids caused by rifampin. * Emphasize the importance of completing the full course of therapy, even after symptom resolution, to prevent relapse and drug resistance. * Hepatotoxicity is a significant concern; educate patients on signs and symptoms (jaundice, dark urine, abdominal pain, fatigue) and to report them immediately. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Local protocols may dictate specific dosing and management strategies.